Signatera is a personalized and highly sensitive blood test that detects circulating tumor DNA (ctDNA). A substantial level of ctDNA detected by this assay suggests a greater quantity of tumor-derived DNA fragments in the bloodstream. This can indicate the presence of residual disease, recurrence after treatment, or potentially a more aggressive tumor. For example, a higher level post-surgery might suggest a greater risk of recurrence compared to a lower, or undetectable, level.
Monitoring ctDNA levels through assays like Signatera offers several key advantages in cancer care. It allows for early detection of molecular residual disease, potentially enabling earlier intervention. Dynamic tracking of ctDNA levels over time can provide insights into treatment response and disease progression. This personalized approach can inform treatment decisions, leading to more effective and targeted therapies. The development and refinement of such liquid biopsy technologies represent a significant advancement in cancer diagnostics and management.
